Mammal Patents (Class 800/14)
-
Publication number: 20130247235Abstract: Genetically modified non-human animals are provided that comprise an immunoglobulin heavy chain locus comprising an unrearranged human heavy chain variable region nucleotide sequence comprising an addition of at least one histidine codon or a substitution of at least one endogenous non-histidine codon with a histidine codon. Compositions and methods for making the genetically modified non-human animals as described herein are provided. Non-human animals capable of expressing an antigen-binding protein characterized by pH-dependent antigen binding, enhanced recyclability and/or enhanced serum half-life are also provided.Type: ApplicationFiled: March 15, 2013Publication date: September 19, 2013Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: John MCWHIRTER, Lynn MACDONALD, Andrew J. MURPHY
-
Patent number: 8524976Abstract: The present invention relates to a ?-L-iduronidase knock-out mouse. More particularly, this invention relates to a ?-L-iduronidase knock-out mouse to be designed for developing a treatment or an agent for mucopolysaccharidosis type I (Hurler syndrome or Hurler-Scheie syndrome) as an animal model.Type: GrantFiled: September 17, 2009Date of Patent: September 3, 2013Assignee: Medigenbio CorporationInventor: Thong-Gyu Jin
-
Patent number: 8518699Abstract: The invention relates to a modified lymphoid cell having gene conversion fully or partially replaced by hypermutation, wherein said cell has no deleterious mutations in genes encoding paralogues and analogues of the RAD51 protein, and wherein said cell is capable of directed and selective genetic diversification of a target nucleic acid by hypermutation or a combination of hypermutation and gene conversion. The invention also relates to a method for diversifying any transgenic target gene in said cell. Preferably, the target gene is integrated into the immunoglobulin light or heavy chain locus by targeted integration.Type: GrantFiled: February 23, 2005Date of Patent: August 27, 2013Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit, GmbHInventors: Jean-Marie Buerstedde, Hiroshi Arakawa
-
Publication number: 20130219533Abstract: In some aspects, the invention provides compositions and methods for inhibiting viral infection. In some aspects, the invention provides compositions and methods useful for identifying antiviral compounds.Type: ApplicationFiled: June 17, 2011Publication date: August 22, 2013Applicant: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Thijn R. Brummelkamp, Jan E. Carette
-
Publication number: 20130219532Abstract: The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes, such as protecting plants from fungal infections; treating fungal infections of animals, especially humans; and prevention of food spoilage.Type: ApplicationFiled: March 27, 2013Publication date: August 22, 2013Applicant: Commonwealth Scientific and Industrial Research OrganisationInventors: Peter David East, Susan Elizabeth Brown
-
Patent number: 8513485Abstract: The invention provides methods for isolating cell-type specific mRNAs by selectively isolating ribosomes or proteins that bind mRNA in a cell type specific manner, and, thereby, the mRNA hound to the ribosomes or proteins that bind mRNA. Ribosomes, which are riboprotein complexes, bind mRNA that is being actively translated in cells. According to the methods of the invention, cells are engineered to express a molecularly tagged ribosomal protein or protein that binds mRNA by introducing into the cell a nucleic acid comprising a nucleotide sequence encoding a ribosomal protein or protein that binds mRNA fused to a nucleotide sequence encoding a peptide tag. The tagged ribosome or mRNA binding protein can then be isolated, along with the mRNA bound to the tagged ribosome or mRNA binding protein, and the mRNA isolated and further used for gene expression analysis.Type: GrantFiled: May 10, 2011Date of Patent: August 20, 2013Assignee: Envoy Therapeutics, Inc.Inventors: Nathaniel Heintz, Tito A. Serafini, Andrew W. Shyjan
-
Publication number: 20130212722Abstract: Disclosed are materials and methods for creating customizable traits in animals. In the demonstration of the principle of the subject invention, a keratin-14 specific promoter is used with, red fluorescent protein in the loxp cassette, dominant black (?G23) beta defensin 103 in the pigment cassette, and an SV40 (with intron) polyadenylation sequence. When Cre recombinase (or HTNCre) is applied to the animal's skin in a carrier base (e.g., lipid bilayers), fur is permanently genetically modified to turn black in the shape in which it was applied.Type: ApplicationFiled: February 15, 2013Publication date: August 15, 2013Applicant: MICE WITH HORNS, LLCInventor: Mice With Horns, LLC
-
Publication number: 20130212724Abstract: Provided is a composition for regenerating hair follicles comprising CD36-expressing dermal sheath cells (DSc).Type: ApplicationFiled: September 29, 2010Publication date: August 15, 2013Applicant: SHISEIDO COMPANY, LTD.Inventors: Yuzo Yoshida, Tsutomu Soma, Shigeyoshi Fujiwara
-
Publication number: 20130212723Abstract: Disclosed are materials and methods for creating customizable traits in animals. In the demonstration of the principle of the subject invention, a keratin-14 specific promoter is used with red fluorescent protein in the loxp cassette, dominant black (?G23) beta defensin 103 in the pigment cassette, and an SV40 (with intron) polyadenylation sequence. When Cre recombinase (or HTNCre) is applied to the animal's skin in a carrier base (e.g., lipid bilayers), fur is permanently genetically modified to turn black in the shape in which the HTNCre was applied.Type: ApplicationFiled: March 15, 2013Publication date: August 15, 2013Applicant: MICE WITH HORNS, LLCInventor: Mice With Horns, LLC
-
Publication number: 20130203648Abstract: The invention relates to obtaining a preparation of recombinant human PLTP from the milk of a transgenic animal containing in its genome one or more copies of a transgene comprising a polynucleotide coding for human PTLP, placed under transcriptional control of a promoter permitting its specific expression in the cells of the mammary glands of said animal. The recombinant human PLTP preparation obtained can be used in the prevention or treatment of septic shock.Type: ApplicationFiled: April 6, 2011Publication date: August 8, 2013Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), BIOPROTEIN TECHNOLOGIES SAInventors: Pierre-Jean Ripoll, Laurent Lagrost
-
Patent number: 8502017Abstract: The present disclosure describes an animal model of central neuropathic pain relevant to spinal cord injury, as well as methods of using the model to screen for therapeutic agents and to test existing therapies.Type: GrantFiled: August 14, 2009Date of Patent: August 6, 2013Inventor: Scott P. Falci
-
Publication number: 20130198878Abstract: Disclosed herein are homozygously modified organisms and methods of making and using these organisms.Type: ApplicationFiled: March 14, 2013Publication date: August 1, 2013Applicant: C/O SANGAMO BIOSCIENCES, INC.Inventor: C/O SANGAMO BIOSCIENCES, INC.
-
Publication number: 20130185818Abstract: A method to generate siRNAs in vivo is described, as are constructs and compositions useful in the method. The method does not depend on the use of DNA or synthetic constructs that contain inverted duplications or dual promoters so as to form perfect or largely double-stranded RNA. Rather, the method depends on constructs that yield single-stranded RNA transcripts, and exploits endogenous or in vivo-produced miRNAs or siRNAs to initiate production of siRNAs. The miRNAs or siRNAs guide cleavage of the transcript and set the register for production of siRNAs (usually 21 nucleotides in length) encoded adjacent to the initiation cleavage site within the construct. The method results in specific formation of siRNAs of predictable size and register (phase) relative to the initiation cleavage site. The method can be used to produce specific siRNAs in vivo for inactivation or suppression of one or more target genes or other entities, such as pathogens.Type: ApplicationFiled: March 14, 2013Publication date: July 18, 2013Applicant: State of Oregon acting by and through the State Board of Higher Education on behalf of Oregon StatInventor: State of Oregon acting by and through the State Board of Higher Education on behalf of Oregon Sta
-
Publication number: 20130185820Abstract: The invention provides genetically modified non-human animals that express a humanized MHC II protein (humanized MHC II ? and ? polypeptides), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.Type: ApplicationFiled: March 11, 2013Publication date: July 18, 2013Applicant: REGENERON PHARMACEUTICALS, INC.Inventor: REGENERON PHARMACEUTICALS, INC.
-
Publication number: 20130185819Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I polypeptide and/or human or humanized ?2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.Type: ApplicationFiled: March 11, 2013Publication date: July 18, 2013Applicant: REGENERON PHARMACEUTICALS, INC.Inventor: REGENERON PHARMACEUTICALS, INC.
-
Publication number: 20130179999Abstract: Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.Type: ApplicationFiled: April 22, 2011Publication date: July 11, 2013Applicant: COLD SPRING HARBOR LABORATORYInventors: Gregory J. Hannon, Sihem Cheloufi
-
Publication number: 20130174289Abstract: The invention relates to methods to identify new SLC41A1 functions at the cell, tissue, organ and organism level. In part, it is related to methods useful in (a) identifying molecules that bind SLC41A1 polypeptides, which (b) modulate SLC41A1 related Na+/Mg2+ exchanger activity or its cellular or tissue specific expression. Thus, the invention comprises SLC41A1 mutation libraries, SLC41A1 specific antibodies, their generation and finding as well as an inducible conditional SLC41A1 knock out mice model and inducible conditional knock out SLC41A1 cell lines.Type: ApplicationFiled: September 15, 2011Publication date: July 4, 2013Applicant: FBN - Leibnitz-Institut fur NutztierbiologieInventors: Monika Schweigel, Martin Kolisek
-
Publication number: 20130133092Abstract: The present invention relates to a method of sequence specific recombination of DNA in eukaryotic cells utilizing att sequences from the bacteriophage lambda. A particular embodiment of the invention relates to a method further comprising performing the sequence specific recombination of DNA with an Int and a Xis factor. The present invention further relates to vectors containing each of these sequences and their use as medicaments.Type: ApplicationFiled: November 1, 2012Publication date: May 23, 2013Inventor: Dr. Peter Droge
-
Publication number: 20130131317Abstract: The invention features a process of expressing secreted recombinant human alpha-fetoprotein (rHuAFP) in the milk or urine of transgenic mammals.Type: ApplicationFiled: January 25, 2013Publication date: May 23, 2013Applicant: Merrimack Pharmaceuticals, Inc.Inventor: Merrimack Pharmaceuticals, Inc.
-
Publication number: 20130117870Abstract: Compositions and methods for use of TALENs to make genetically modified livestock or other animals are set forth. Some of the embodiments of the invention provide for making an founder animal that is completely free of all unplanned genetic modifications. Some embodiments are directed to removing genetic faults in established breeds without making other alterations to the genome. Other embodiments are directed to particular tools or processes such as a TALENs with a preferred truncation.Type: ApplicationFiled: August 24, 2012Publication date: May 9, 2013Inventors: Scott C. Fahrenkrug, Daniel F. Carlson
-
Publication number: 20130109087Abstract: The present invention provides a method for producing a transgenic (Tg) non-human animal capable of developing an enhanced humoral immune response against an antigen as compared to a non-transgenic control animal of the same species, comprising introducing into said non-human animal a genetic construct providing for enhanced MHC class I-related neonatal Fc receptor (FcRn) activity. Also provided a Tg non-human animal comprising a genetic construct providing for enhanced FcRn activity, as well as the use of such animal in a non-therapeutical method. Therapeutic genetic constructs and methods are also provided. The present invention further provides methods for producing immunoglobulins.Type: ApplicationFiled: October 10, 2012Publication date: May 2, 2013Applicants: EOTVOS LORAND UNIVERSITY, AGRICULTURAL BIOTECHNOLOGY CENTERInventors: AGRICULTURAL BIOTECHNOLOGY CENTER, Eotvos Lorand University
-
Publication number: 20130111616Abstract: The invention provides genetically modified non-human animals that express a humanized MHC II protein (humanized MHC II ? and ? polypeptides), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.Type: ApplicationFiled: October 26, 2012Publication date: May 2, 2013Applicant: REGENERON PHARMACEUTICALS, INC.Inventor: REGENERON PHARMACEUTICALS, INC.
-
Publication number: 20130111617Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I polypeptide and/or human or humanized ?2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.Type: ApplicationFiled: October 26, 2012Publication date: May 2, 2013Applicant: REGENERON PHARMACEUTICALS, INC.Inventor: REGENERON PHARMACEUTICALS, INC.
-
Patent number: 8431767Abstract: Transgenic immunodeficient non-human animals according to embodiments of the present invention are described which include in their genome a nucleic acid encoding xenogeneic Stem Cell Factor operably linked to a promoter. Administration of xenogeneic hematopoetic stem cells to the inventive transgenic animals results in engraftment of the xenogeneic hematopoetic stem cells and xenogeneic leukocytes are produced in the animals, without conditioning such as without conditioning by irradiation and without conditioning by a radiomimetic agent.Type: GrantFiled: November 9, 2010Date of Patent: April 30, 2013Assignees: The Jackson Laboratory, University of Massachusetts Medical SchoolInventors: Leonard D. Shultz, Dale L. Greiner
-
Patent number: 8426675Abstract: The invention relates to recombinant vectors for inducible and/or tissue specific expression of double-stranded RNA molecules that interfere with the expression of a target gene. In certain embodiments, the invention relates to the use of Tet (tetracycline)-responsive RNA Polymerase II (Pol II) promoters (e.g., TetON or TetOFF) to direct inducible knockdown in certain cells of an integrated or an endogenous gene, such as p53. The invention also relates to a method for producing transgenic animals (e.g., mice) expressing inducible (such as tetracycline-regulated), reversible, and/or tissue-specific double-stranded RNA molecules that interfere with the expression of a target gene.Type: GrantFiled: June 7, 2011Date of Patent: April 23, 2013Assignee: Cold Spring Harbor LaboratoryInventors: Ross Dickins, Scott W. Lowe, Gregory J. Hannon
-
Publication number: 20130091591Abstract: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example.Type: ApplicationFiled: August 29, 2012Publication date: April 11, 2013Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: Hai U. Wang, Zhoufeng Chen, David J. Anderson
-
Patent number: 8410333Abstract: The present invention concerns methods and means to produce humanized antibodies from transgenic non-human animals. The invention specifically relates to novel immunoglobulin heavy and light chain constructs, recombination and transgenic vectors useful in making transgenic non-human animals expressing humanized antibodies, transgenic animals, and humanized immunoglobulin preparations.Type: GrantFiled: July 29, 2009Date of Patent: April 2, 2013Assignee: Therapeutic Human Polyclonals, Inc.Inventors: Roland Buelow, Wim van Schooten, Josef Platzer
-
Publication number: 20130067609Abstract: The present invention relates to nucleic acid sequences and cellular proteins encoded by these sequences that are involved in infection or are otherwise associated with the life cycle of one or more pathogens.Type: ApplicationFiled: June 14, 2010Publication date: March 14, 2013Inventors: Donald Rubin, Robert Gilmore, Thomas Hodge, Natalie McDonald
-
Publication number: 20130042334Abstract: The invention provides a chimeric enzyme comprising at least one catalytic domain of a RNA triphosphatase, at least one catalytic domain of a guanylyltransferase, at least one catalytic domain of a N7-guanine methyltransferase, and at least one catalytic domain of a DNA-dependant RNA polymerase. The invention also provides pharmaceutical composition comprising said chimeric enzyme and uses of said chimeric enzyme.Type: ApplicationFiled: April 15, 2011Publication date: February 14, 2013Applicant: EukarysInventor: Philippe Jais
-
Patent number: 8373017Abstract: Reconstituted human breast tumor models are disclosed. The models, which are incorporated into mice, provide actual tumors that arise spontaneously, thereby mimicking naturally occurring breast cancer. The tumors are genetically human, because they arise from human mammary tissues that develop from human mammary epithelial cells implanted into host mice. Prior to implantation, the mammary epithelial cells are genetically modified to contain either: (a) a recombinant human oncogene and an SV40er; or (b) a recombinant human oncogene, a transgene or shRNA that inhibits the p53 pathway, and a transgene or shRNA that inhibits the Rb pathway.Type: GrantFiled: December 6, 2005Date of Patent: February 12, 2013Assignee: AVEO Pharmaceuticals, Inc.Inventors: Min Wu, Charlotte Kuperwasser, Murray Robinson
-
Patent number: 8367887Abstract: It is intended to provide a simple normal-tension glaucoma model capable of spontaneously, age-dependently and surly developing conditions similar to symptoms of normal-tension glaucoma which occurs more frequently in elder people, and a method of evaluating therapeutic effect on normal-tension glaucoma whereby a drug useful in treating and diagnosing can be conveniently screened by using the normal-tension glaucoma model. A normal-tension glaucoma model comprising a nonhuman mammal, which is deficient in a transcriptional regulator NF-?Bp50 and thus spontaneously develops the normal-tension glaucoma symptom age-relatedly, an organ or a tissue thereof or cells collected from any of the same.Type: GrantFiled: July 11, 2008Date of Patent: February 5, 2013Assignee: Shinshu UniversityInventors: Takuma Hayashi, Yasuko Takahashi, Tomoko Yanagidaira, Shunichiro Taniguchi, Toshinori Murata
-
Publication number: 20130031648Abstract: The present relates to use of follistatin-like related gene (FLRG) to increase muscle mass in a subject. As such, methods of ameliorating the severity of a pathologic condition characterized, at least in part, by a decreased amount, development or metabolic activity of muscle are provided. In addition transgenic non-human mammals expressing FLRG and having increased muscle mass as compared to a corresponding mammal having a myostatin-null mutation or a decreased level of myostatin are provided.Type: ApplicationFiled: August 6, 2012Publication date: January 31, 2013Inventor: Se-Jin Lee
-
Publication number: 20130024959Abstract: The present invention relates to a method of producing a cell comprising a conditionally active transgene in its genome, the method comprising (a) introducing into the cell a targeting vector, wherein the targeting vector comprises (i) a 5? recombinase recognition site specifically recognised by a first recombinase, wherein the first recombinase is endogenously present in the cell or wherein the first recombinase or a nucleic acid molecule encoding said first recombinase in expressible form is introduced into the cell; followed by (ii) a 5? recombinase recognition site specifically recognised by a second recombinase, wherein the second recombinase is not endogenously present or is not active in the cell; followed by (iii) a selection cassette comprising a positively selectable marker gene; followed by (iv) a 3? recombinase recognition site specifically recognised by a third recombinase, wherein the third recombinase is not endogenously present or is not active in the cell; followed by (v) the transgene; folloType: ApplicationFiled: November 24, 2010Publication date: January 24, 2013Applicants: UNIVERSITY OF FRANKFURT-MEDICAL SCHOOL, HELMHOLTZ ZENTRUM MÜNCHEN-DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)Inventors: Laura Schebelle, Frank Schnütgen, Thomas Floss
-
Publication number: 20130024960Abstract: An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.Type: ApplicationFiled: July 8, 2010Publication date: January 24, 2013Applicants: UCL BUSINESS PLC, ST. JUDE CHILDREN'S RESEARCH HOSPITAL, THROMBOSIS RESEARCH INSTITUTEInventors: Amit Nathwani, Natalie Ward, Adrian Thrasher, Edward Tuddenham, John McVey, John Gray, Andrew Davidoff
-
Patent number: 8357832Abstract: A trifusion reporter plasmid is described that comprises a plasmid operably coupled to a mammalian FGF1B promoter that is operably coupled to a bioluminescence gene fused to a fluorescence gene fused to a nuclear medical imaging gene. The new reporter allows in vivo or ex vivo detection of gene expression in three different ways, in addition to traditional in vitro detection methods. Transgenic animals containing this new trifusion reporter and uses of same are described.Type: GrantFiled: January 26, 2012Date of Patent: January 22, 2013Assignee: National Health Research InstitutesInventors: Kurt M. Lin, Ing-Ming Chiu
-
Publication number: 20120331575Abstract: The invention provides a non-human transgenic animal comprising a transgene encoding angiogenin and food products comprising or obtained from the non-human transgenic animal and uses thereof.Type: ApplicationFiled: November 18, 2010Publication date: December 27, 2012Applicants: Agriculture Victoria Services PTY LTD, Murray Goulburn Co-Operative Co. LimitedInventors: Peter Hobman, Matthew McDonagh, Benjamin Cocks, Angus Tester
-
Patent number: 8329981Abstract: A genetically modified mouse characterized in that it does not comprise a nucleic acid sequence which itself encodes any endogenous immunoglobulin heavy chain constant region locus polypeptide.Type: GrantFiled: April 6, 2011Date of Patent: December 11, 2012Assignee: Crescendo Biologics LimitedInventor: Marianne Bruggemann
-
Publication number: 20120304317Abstract: The invention provides transgenic rodents, particularly mice, expressing truncated versions of the Disrupted-in-Schizophrenia-1 (DISC1) gene and showing Schizophrenia-related neural and behavioral phenotypes. The rodents of the invention have (1) a plurality of copies of a heterologous truncated Disc1 genomic DNA sequence which includes at least 1 stop codon after exon 8 such as to encode a Disc1 polypeptide truncated before exon 9; (2) 2 copies of endogenous Disc1 genomic DNA sequence encoding full length Disc1 polypeptide. Also provided are related materials and methods.Type: ApplicationFiled: July 16, 2009Publication date: November 29, 2012Applicants: THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN, WYETH PHARMACEUTICALS INC., TMRI LIMITEDInventors: Sanbing Shen, Gernot Riedel, David St. Clair
-
Patent number: 8319007Abstract: Disclosed herein are an ?1/CaV3.1 double knockout mouse or ?1?/?; Emx1-Cre mouse with enhanced essential tremor and a screening method of therapeutic agents for essential tremor by using the same. The ?1/CaV3.1 double knockout mouse or ?1?/?; Emx1-Cre mouse of the present invention may be usefully used for development of therapeutic agents for essential tremor because the mouse exhibits essential tremor strong and evident enough to be visually confirmed, compared to an ?1 knockout mouse.Type: GrantFiled: April 7, 2010Date of Patent: November 27, 2012Assignee: Korea Advanced Institute of Science and TechnologyInventors: Daesoo Kim, Ki Young Chang, Hyeyeon Park, Young Gyun Park
-
Publication number: 20120291145Abstract: The present invention provides for a transgenic non-human animal whose cells contain a DNA sequence comprising: (a) a nerve tissue specific promoter; and (b) a DNA sequence which encodes a receptor for advanced glycation endproducts (RAGE), wherein the promoter and the DNA sequence which encodes the receptor for advanced glycation endproducts (RAGE) are operatively linked to each other and integrated in the genome of the non-human animal, and wherein said non-human animal exhibits a reduced amount of cerebral tissue infarcted following a transient middle cerebral artery occlusion compared to an identical non-human animal lacking said DNA sequence.Type: ApplicationFiled: January 31, 2012Publication date: November 15, 2012Inventors: David M. Stern, Ann Marie Schmidt, Shi Du Yan
-
Publication number: 20120272349Abstract: The present invention provides a preparation method of a chimeric embryo and a chimeric rat, which is characterized by contacting a rat pluripotent stem cell and a host embryo in the presence of an ES cell differentiation inhibitor. The method includes (a) a step for contacting a fertilized host embryo collected from a female rat and a rat pluripotent stem cell in the presence of an ES cell differentiation suppressant, and (b) a step for culturing the host embryo in contact with the rat pluripotent stem cell to form a chimeric embryo.Type: ApplicationFiled: November 30, 2010Publication date: October 25, 2012Applicants: DS PHARMA BIOMEDICAL CO., LTD., NATIONAL CANCER CENTERInventors: Takahiro Ochiya, Masaki Kawamata
-
Publication number: 20120266328Abstract: The invention is directed to polypeptides having any cellulolytic activity, e.g., a cellulase activity, e.g., endoglucanase, cellobiohydrolase, beta-glucosidase, xylanase, mannanse, ?-xylosidase, arabinofuranosidase, and/or oligomerase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The polypeptides of the invention can be used in a variety of pharmaceutical, agricultural, food and feed processing and industrial contexts. The invention also provides compositions or products of manufacture comprising mixtures of enzymes comprising at least one enzyme of this invention.Type: ApplicationFiled: January 20, 2012Publication date: October 18, 2012Applicant: BP CORPORATION NORTH AMERICA INC.Inventors: KEVIN A. GRAY, LISHAN ZHAO, MICHELLE H. CAYOUETTE
-
Patent number: 8288608Abstract: The present invention provides transgenic non-human animals and non-human mammalian somatic and germ cells harbouring a human DNA sequence encoding Alzheimer's Disease (AD) derived tau protein, capable of inducing AD pathology in transgenic animals. Alzheimer's tau protein is expressed on specific genetic backgrounds allowing also simulation of different human diseases including hypertension, diabetes, hyper-cholesterolemia, which are associated with neurodegeneration and are considerable risk factors for AD development. Transgenic animals and cells of the present invention exhibit neurofibrillary pathology and may serve as in vivo and also in vitro assay systems for screening and developing therapeutic and preventive substances and also diagnostic markers and probes for tauopathies and AD.Type: GrantFiled: July 9, 2003Date of Patent: October 16, 2012Assignee: AXON Neuroscience SEInventors: Eva Kontsekovà, Peter Filipcik
-
Publication number: 20120258537Abstract: Method of preparing I-CreI meganuclease variants having a modified cleavage specificity, variants obtainable by said method and their applications either for cleaving new DNA target or for genetic engineering and genome engineering for non-therapeutic purposes. Nucleic acids encoding said variants, expression cassettes comprising said nucleic acids, vectors comprising said expression cassettes, cells or organisms, plants or animals except humans, transformed by said vectors.Type: ApplicationFiled: March 16, 2012Publication date: October 11, 2012Applicant: CELLECTISInventors: Philippe DUCHATEAU, Frédéric Paques
-
Publication number: 20120259093Abstract: The invention features a process of expressing secreted recombinant human alpha-fetoprotein (rHuAFP) in the milk or urine of transgenic mammals.Type: ApplicationFiled: April 13, 2012Publication date: October 11, 2012Applicant: Merrimack Pharmaceuticals, Inc.Inventors: Stace LINDSAY, Robert Mulroy, Daniel Semeniuk
-
Publication number: 20120255045Abstract: The invention relates to vectors for the inducible expression of RNA molecules in eukaryotic, particularly mamType: ApplicationFiled: April 3, 2012Publication date: October 4, 2012Applicant: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.Inventors: Thomas Tuschl, Tilmann Achsel, Reinhard Lührmann, Jutta Meyer
-
Publication number: 20120255040Abstract: The present invention relates in a first aspect to a cell model containing chondrocytes whereby said chondrocytes contain a first heterologous nucleic acid sequence operably linked with a mb1 promoter sequence. In another aspect, the present invention relates to a cell model, in particular, to a transgenic animal model whose genome comprises a first heterologous nucleic acid sequence encoding a recombinase and/or restriction enzyme operably linked to a chondrocyte specific promoter, and a second heterologous nucleic acid sequence encoding a target peptide of interest wherein the second nucleic acid sequence further comprises recombination sequences or restriction site for the enzyme encoded by the first heterologous nucleic acid sequence. In addition, methods for screening foreign agent or methods for testing the efficacy and/or efficiency of an agent are provided.Type: ApplicationFiled: March 30, 2011Publication date: October 4, 2012Inventors: Kai Dittmann, Juergen Wienands
-
Publication number: 20120255046Abstract: Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating a library of recombinant adeno-associated viral capsid proteins are also provided.Type: ApplicationFiled: May 15, 2012Publication date: October 4, 2012Applicant: The Board of Trustees of The Leland Stanford UniversityInventors: MARK KAY, Dirk Grimm
-
Patent number: 8278499Abstract: Disclosed is a nonhuman animal showing the symptoms of human nonalcoholic steatohepatitis which is obtained by transplanting human hepatocytes into an immunodeficient hepatopathic nonhuman animal to produce a chimeric nonhuman animal and then transplanting human hepatocytes that are propagated in the body of the chimeric nonhuman animal into an immunodeficient hepatopathic nonhuman animal of the same species as the immunodeficient hepatopathic nonhuman animal described above, as well as a nonhuman animal showing the symptoms of human fatty liver which is obtained by transplanting human hepatocytes into an immunodeficient hepatopathic nonhuman animal to produce a chimeric nonhuman animal.Type: GrantFiled: June 13, 2007Date of Patent: October 2, 2012Assignees: Hiroshima Industrial Promotion Organization, Phoenixbio Co., Ltd., Hiroshima UniversityInventors: Chise Mukaidani, Katsutoshi Yoshizato, Miho Kataoka
-
Publication number: 20120240247Abstract: The c-Jun NH2-terminal kinase (JNK) group of MAP kinases are activated by exposure of cells to environmental stress. The role of JNK in the brain was examined by targeted disruption of the gene that encodes the neuronal isoform JNK3. It was found that JNK3 is required for the normal response to seizure activity. Methods of screening for molecules and compounds that decrease JNK3 expression or activity are described. Such molecules or compounds are useful for treating disorders involving excitotoxicity such as seizure disorders, Alzheimer's disease, Huntington disease, Parkinson's disease, and ischaemia.Type: ApplicationFiled: December 16, 2011Publication date: September 20, 2012Inventors: Roger J. Davis, Richard A. Flavell, Pasko Rakic, Alan J. Whitmarsh, Chia-Yi Kuan, Derek Di Yang